Synergistic and Persistent Effect of T-Cell Immunotherapy with Anti-CD19 or Anti-CD38 Chimeric Receptor on B-Cell Lymphoma in Conjunction with Rituximab
0
Citation
0
Reference
10
Related Paper
Cell therapy
CAR T-cell therapy
Cite
Citations (0)
Chimeric antigen receptor (CAR) T cell therapies targeting CD19 and CD22 have been successful for treating B cell cancers, but CAR T cells targeting non–B cell cancers remain unsuccessful. We propose that rather than being strictly a side effect of therapy, the large number of CAR interactions with normal B cells may be a key contributor to clinical CAR T cell responses.
CAR T-cell therapy
Cell therapy
Cite
Citations (8)
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic effects, and the manufacture of the cells is complex. Natural killer (NK) cells that have been modified to express an anti-CD19 CAR have the potential to overcome these limitations.
Lymphokine-activated killer cell
Cite
Citations (1,597)
Cite
Citations (1,498)
Chimeric antigen receptor T (CAR-T) cell immunotherapy shows potential and guarantee for clinical application in solid tumor treatment, although a section of difficulties must be overcome. Compared with conventional antitumor therapies, the advantages of CAR-T cell treatment include high specificity, great killing power, and long-term effectiveness. But various difficulties in treating solid tumors by CAR-T immunotherapy include intracellular signaling of CARs, immune escape due to antigenic heterogeneity of malignant tumors, physical or cytokine barriers that prevent CAR-T cell entry or limit their persistence, tumor microenvironment of other immunosuppressive molecules, and side effects. This paper describes CAR-T immunotherapy's mechanisms, development, and applications and discusses the status, difficulties, solutions, and future directions of treating solid tumors by CAR-T immunotherapy.
Cite
Citations (1)
Cellular immunotherapy is recognized as the fourth tumor treatment after surgery, radiotherapy and chemotherapy.Chimeric antigen receptor (CAR)-T-cell therapy belongs to adoptive cellular immunotherapy.CAR-T not only has made great breakthroughs in cancer treatment, but also has good application prospects in the treatment of infectious diseases and autoimmune diseases.This article reviews the development history, clinical applications, current problems and the latest research progress of CAR-T cell immunotherapy.
Key words:
Chimeric antigen receptor; T cell; Immunotherapy; Tumor
Cell therapy
Cancer Immunotherapy
Cite
Citations (0)
Abstract We have analyzed the blood B cell subpopulations of children with systemic lupus erythematosus (SLE) and healthy controls. We found that the normal recirculating mature B cell pool is composed of four subsets: conventional naive and memory B cells, a novel B cell subset with pregerminal center phenotype (IgD+CD38+centerin+), and a plasma cell precursor subset (CD20−CD19+/lowCD27+/++ CD38++). In SLE patients, naive and memory B cells (CD20+CD38−) are ∼90% reduced, whereas oligoclonal plasma cell precursors are 3-fold expanded, independently of disease activity and modality of therapy. Pregerminal center cells in SLE are decreased to a lesser extent than conventional B cells, and therefore represent the predominant blood B cell subset in a number of patients. Thus, SLE is associated with major blood B cell subset alterations.
Immunoglobulin D
Memory B cell
Blood cell
Naive B cell
Cite
Citations (255)
Cell therapy
Cite
Citations (14)
Abstract Backgroud : The unprecedented efficacy of chimeric antigen receptor (CAR) T-cell immunotherapy of CD19 + B-cell malignancies has opened a new and useful way for the treatment of malignant tumor. Nonetheless, there are still formidable challenges in the field of CAR-T cell therapy, such as the biodistribution of CAR-T cells in vivo. Methods : We demonstrated the distribution of CAR-T cells in the absence of target cells or with target cells in the mice and the dynamic changes in the patient blood over time after infusion were deteced by qPCR and FACS. Results : CAR-T cells still proliferated in the mice without target cells and peaked at 2 weeks. However, CAR-T cells did not increase significantly in the presence of target cells within 2 weeks after infusion, but expanded at 6 weeks. In the clinical trial, we found that CAR-T cells peaked at 7-21days after infusion and can last for as long as 510 days in the peripheral blood of patients. Simultaneously, mild side-effects were noted which can be effectively controlled within two months in these patients. Conclusions : CAR-T cells can expand themselves with or without target cells in mice. CAR-T cells can persistence for a long time in patients.
Cell therapy
Cite
Citations (0)
Some patients with hematologic malignancies as acute lymphoblastic leukemia (ALL), can achieve complete remission (CR) after chimeric antigen receptor T cell (CAR-T) immunotherapy. However, many constraints still limit the wide application of CAR-T immunotherapy in patients with hematological malignancies and other cancers, especially in patients with solid tumors. The main challenges related to CAR-T immunotherapy include: relapse caused by immune escape of tumor antigens, cytokine release syndrome (CRS), poor survival time in vivo, low infiltration capacity and inactivation of CAR-T in solid tumors, etc.. This article summarizes effects and problems of CAR-T immunotherapy in clinical trials for hematological malignancies, and how to use comprehensive treatment and biotechnology strategies to solve the current problems, in order to improve safety and effectiveness of CAR-T immunotherapy, and expand clinical benefits of CAR-T immunotherapy for patients with different tumors.
Key words:
Immunotherapy, adoptive; Receptors, chimeric antigen; Hematologic neoplasms; Chimeric antigen receptor-T cell; Solid tumors; Chimeric antigen receptor T cells immunotherapy; Combined modality therapy
Cancer Immunotherapy
Cite
Citations (0)